Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to Buy at BidaskClub

BidaskClub cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports.

Several other equities analysts have also weighed in on ENTA. Zacks Investment Research raised Enanta Pharmaceuticals from a hold rating to a buy rating and set a $99.00 price objective for the company in a report on Friday, May 10th. Wolfe Research assumed coverage on Enanta Pharmaceuticals in a report on Friday, May 24th. They set an outperform rating and a $117.00 price objective for the company. Finally, Berenberg Bank raised Enanta Pharmaceuticals from a hold rating to a buy rating and increased their price objective for the company from $80.00 to $120.00 in a report on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $111.20.

Shares of ENTA stock traded down $1.11 during trading on Thursday, hitting $96.24. The company’s stock had a trading volume of 3,371 shares, compared to its average volume of 136,555. The firm has a market cap of $1.88 billion, a PE ratio of 27.53 and a beta of 1.18. Enanta Pharmaceuticals has a 52 week low of $64.08 and a 52 week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.29. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. Enanta Pharmaceuticals’s quarterly revenue was down 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.61 earnings per share. On average, equities research analysts anticipate that Enanta Pharmaceuticals will post 1.9 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Montreal Can increased its position in shares of Enanta Pharmaceuticals by 33.0% during the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 216 shares during the period. Arizona State Retirement System boosted its stake in Enanta Pharmaceuticals by 6.4% during the fourth quarter. Arizona State Retirement System now owns 24,229 shares of the biotechnology company’s stock worth $1,716,000 after acquiring an additional 1,460 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in Enanta Pharmaceuticals by 36.0% during the fourth quarter. Xact Kapitalforvaltning AB now owns 3,400 shares of the biotechnology company’s stock worth $241,000 after acquiring an additional 900 shares in the last quarter. Rhumbline Advisers boosted its stake in Enanta Pharmaceuticals by 22.9% during the fourth quarter. Rhumbline Advisers now owns 46,753 shares of the biotechnology company’s stock worth $3,312,000 after acquiring an additional 8,722 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $489,000. 89.64% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Bull Market

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.